Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 11,338 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Uncontrolled Hypertension
Interventions: CIN-107, Placebo; Drug
Lead sponsor: CinCor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more

Conditions: Influenza, Human
Interventions: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 1,778 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Mobile, Alabama • Anaheim, California • Redding, California + 17 more

Conditions: Heart Failure, Ventricular Arrythmia
Interventions: LBBAP Implant with a CSP ICD Lead; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Huntsville, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 13 more

Conditions: Gastrointestinal Cancer
Interventions: Raludotatug Deruxtecan (R-DXd); Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Miami Beach, Florida + 5 more

Conditions: Post-Herpetic Neuralgia
Interventions: pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 11 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Conditions: Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting
Interventions: JNJ-42160443, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Birmingham, Alabama • Tucson, Arizona • Laguna Hills, California + 14 more

Conditions: Primary Myelofibrosis, Anemia
Interventions: Luspatercept; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Stanford, California • Jacksonville, Florida + 7 more

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions: Lepodisiran Sodium, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 17,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 222
States / cities: Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more

Conditions: Influenza, Human
Interventions: Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more

Conditions: Bleeding, Colorectal Disorders, Thromboembolism, Tranexamic Acid
Interventions: Tranexamic acid; Drug
Lead sponsor: Kristen Ban; Other
Eligibility: 18 Years to 100 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Interventions: Device; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1983 – 2040
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 111 more

Conditions: Infant, Newborn
Interventions: milk protein formulas, varying carbohydrate/protein sources; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: Up to 8 Days
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 15
States / cities: Aventura, Florida • Tampa, Florida • Coralville, Iowa + 12 more

Conditions: CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Interventions: SYNCAR-001, STK-009, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Synthekine; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2041
U.S. locations: 4
States / cities: Duarte, California • Buffalo, New York • New York, New York + 1 more

Conditions: Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
Interventions: Cisplatin, Conventional Surgery, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Mitotane, Pegfilgrastim; Drug · Procedure · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more

Conditions: Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: levofloxacin; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 78
States / cities: Little Rock, Arkansas • Downey, California • Duarte, California + 65 more

Conditions: Female Sexual Arousal Disorder
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 51
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Interventions: Cetuximab; Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 22
States / cities: Aurora, Colorado • New Britain, Connecticut • Decatur, Illinois + 18 more

Conditions: Acute Pulpitis
Interventions: Brain wave analysis using electroencephalography (EEG)., Numerical rate Scale (NRS); Diagnostic Test
Lead sponsor: Cleveland Dental Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lupus Erythematosus, Systemic
Interventions: Memantine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Homogeneous Emphysema
Interventions: Biologic Lung Volume Reduction; Biological
Lead sponsor: Aeris Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Iowa City, Iowa + 5 more

Conditions: Episodic Migraine
Interventions: DFN-11, Placebo; Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 16
States / cities: Santa Monica, California • Jacksonville, Florida • Maitland, Florida + 13 more

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 19 more

Search by objective public record fields.

A Study of CIN-107 in Patients With Uncontrolled Hypertension

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

ASCEND CSP IDE Study

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Tolerance of Healthy Term Infants Fed Infant Formulas

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Pain Measured by NRS and EEG in Acute Pulpitis

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

DFN-11 Injection in Episodic Migraine With or Without Aura

Diagnosing Epilepsy To EffeCT Change